Dr. Rob DeWit is an operating advisor at Avista Capital Partners. Dr. DeWit is an industry leader who has dedicated more than 35 years to advancing global healthcare, by serving in scientific and leadership roles for Warner-Lambert, Upjohn, Pharmacia, Pfizer, and the WMU Homer Stryker MD School of Medicine Innovation Center. Dr. DeWit most recently served as the President and CEO of MPI Research, a former Avista IV portfolio company sold in 2018 to Charles River Laboratories. Dr. DeWit has extensive experience with non-clinical drug development and corporate cultural change.
Dr. DeWit received a B.S. from Calvin College and a PhD in Toxicology from The University of Michigan. He currently serves as Chairman of the Board of ACP Northern Holdings and on the board of Taconic Biosciences, and previously served as a Director of Inform Diagnostics.